A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment
Rheum 2024 doi: 10.1093/rheumatology/keae432 Epub ahead of print
Deodhar et al. investigated the impact on efficacy and safety of escalating secukinumab dose from 150mg to 300mg Q4W in AS patients who did not achieve inactive disease during an initial 16-week period of 150mg secukinumab. At Week 52, clinical safety response rates were similar across groups continuing with 150mg or escalating to 300mg secukinumab.
The trial (ASLeap) was a randomised, double-blind, parallel-group, multicentre, Phase 4 study, where patients with inadequate response to secukinumab 150mg Q4W at Week 16 were maintained on secukinumab 150mg (n=105) or switched to 300mg (n=101) through to Week 52.
Keywords:
